About NRx
NRx is a publicly listed company based in Wilmington (United States) founded in 2017 by Daniel C Javitt and Jonathan C Javitt. Therapeutics for COVID-19 and neurological disorders are developed. NRx was last valued at $1.5 billion in August 2021. Its chief executive, as recorded, is Jonathan C Javitt. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its competitors include Pardes Biosciences, Vaxxinity and Inimmune; 3 of its 3 listed competitors have raised funding.
Company details
NRx was founded in 2017 and is headquartered in Wilmington, United States. Therapeutics targeting COVID-19 and neurological disorders are developed by the company within the pharmaceutical sector. Operations focus on candidates such as ZYESAMI, which contains aviptadil acetate for respiratory failure in COVID-19, along with NRX-101 and NRX-100 for acute suicidal behavior in bipolar disorder. Clinical development and regulatory processes are managed from the U.S. base.
- Headquarters Wilmington, United States
- Founders Daniel C Javitt, Jonathan C Javitt
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website nrxpharma.com
- Social LinkedIn X Facebook
- Legal Name Nrx Pharmaceuticals, Inc.
- Annual Revenue$1.23 M (USD)as on Dec 31, 2025
- Net Profit-$28.62 M (USD)-13.91as on Dec 31, 2025
- EBITDA-$16.05 M (USD)18.55as on Dec 31, 2025
- Latest Funding Round$25M (USD), Post-IPO
Feb 2022
- Investors
Funding Insights of NRx
- Total Rounds 3
- Last Round Post-IPO — $25M
- First Round $343,045
(Feb 2017)
- Investors Count 1
All 3 funding rounds of NRx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2022 | $25M | Post-IPO | – | – | – |
| Aug 2021 | $30M | Post-IPO | $1.5B | – | – |
| Feb 2017 | $343,045 | Grant | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Aug 2021 | $1.5B | •••••••• |
Last known valuation $1.5B (Aug 2021). 1 investors in total: 1 institutional.
Investors in NRx
NRx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for NRx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NRx
19 people are tracked at NRx (9 in leadership, 9 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Daniel C Javitt | Co-Founder | Leadership |
Jonathan C Javitt | Co-Founder & CEO | Leadership |
Dennis K. McBride | Chief Strategy Officer & Senior Scientist | Leadership |
Matthew Duffy | Chief Business Officer | Leadership |
Rick Panicucci | Chief Technology Officer | Leadership |
Philip T. Lavin | Chief Methodologist | Leadership |
Martin Brecher | Medical Director | Leadership |
Zachary Javitt | Director Of Brand Strategy | Leadership |
Drew Evans | Director Of Digital Communications | Leadership |
Chaim Hurvitz | Director | Board & advisors |
Patrick Flynn | Board Member | Board & advisors |
Harry B. Peled | Clinical Advisor COVID-19 | Board & advisors |
Wayne Pines | Regulatory & Patient Advocacy Adviser | Board & advisors |
Sherry A. Glied | Director | Board & advisors |
Andrew Nierenberg | Advisor | Board & advisors |
Marion Leboyer | Advisor | Board & advisors |
Aaron Gorovitz | Director | Board & advisors |
Melvin L. Morganroth | Clinical Advisor, COVID-19 | Board & advisors |
M. Daniel Gordin | Regulatory Affairs Officer | Team |
Complete people profiles for NRx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of NRx
NRx is a publicly listed company on the NASDAQ with ticker symbol NRXP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Nov 2017
- Listed onNASDAQ: NRXP
- Listed entityNRX Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS6294442099
- Share price$2.70 (-5.26% on the day) · 2026-10-13
- Market capitalisation$116.9M
- EPS (diluted, trailing year)$-0.74
- Volume (last session)553,869
Financials of NRx
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.2M | -$28.6M | -$16.1M |
| 2024 | -$25.1M | -$19.7M | |
| 2023 | -$30.1M | -$27.6M | |
| 2022 | -$39.8M | -$44.3M | |
| 2021 | -$93.1M | -$95.2M |
Detailed financial statements for NRx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of NRx
5 dated milestones of NRx across 5 years, from founding to its latest funding, stage changes and deals.
- Founded NRx is founded.
- Funding First funding round of $343K.
- IPO Lists on the stock exchange (IPO).
- Milestone Reaches Unicorn status.
- Funding Latest funding round, Post-IPO, of $25.0M.
Competitors of NRx
NRx has 3 listed competitors in our database, 3 of them funded. They include Pardes Biosciences, Vaxxinity and Inimmune.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pardesbio.com | 2020 | Berkeley, United States | $51.61M | 29 | Therapeutics for pandemic diseases including SARS-CoV-2 are developed. | |
| vaxxinity.com | 2019 | Dallas, United States | $26.96M | 92 | Vaccines for neurological disorders and infectious diseases are developed. | |
| inimmune.com | 2016 | Missoula, United States | $22M | 35 | Integrated clinical developmental services to treat food allergy, allergic rhinitis, and auto-immune disorders |
Detailed competitors of NRx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NRx
The website of NRx (nrxpharma.com) receives about 9.7K visits a month and ranks #2,517,596 among all websites worldwide, #3,457 in Biotechnology and Pharmaceuticals.
- Monthly visits9.7K
▲ 25.7% vs previous month
- Unique visitors3.6K
per month
- Global rank#2,517,596
among all websites
- Category rank#3,457
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit2.1
- Average visit17 sec
- DevicesDesktop 28% · Mobile 72%
Top companies in Infectious Diseases
3 companies that operate in the same segment as NRx (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 87.11 M | 4,647 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nrx
Complete news archive for NRx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NRx
NRx was founded in 2017.
NRx is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
Jonathan C Javitt is the CEO of NRx, as recorded in our data. They have also founded this company.
Annual revenue of NRx is $1.23M as on Dec 31, 2025.
NRx was founded in 2017 and is headquartered in Wilmington, United States. Therapeutics targeting COVID-19 and neurological disorders are developed by the company within the pharmaceutical sector. Operations focus on candidates such as ZYESAMI, which contains aviptadil acetate for respiratory failure in COVID-19, along with NRX-101 and NRX-100 for acute suicidal behavior in bipolar disorder. Clinical development and regulatory processes are managed from the U.S. base.
NRx's top competitors include Pardes Biosciences, Vaxxinity and Inimmune.
Yes, NRx is publicly traded on NASDAQ under the ticker symbol NRXP.
NRx has 1 investor. Key investors include HHS.
The valuation of NRx is $1.5B as of Aug 2021.